BioPharma Credit PLC (BPCR) Fair Value & Analysis
Financial Services · GB · Market cap $108B
Fair value as of: Aug 20, 2026
From 12 valuation models · updated today
Fair value updated Aug 20, 2026, revised from $0.0200 to $1.50 (+7,400.0%) since Aug 13, 2026. Share price +1.0% over the past month.
A strong business, screening 54% undervalued on our models.
What matters now
- The rarer combination: high quality (75/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case ($1.00). The market is more pessimistic than our downside scenario.
- A fairly wide model range ($1.00 to $1.88) leaves room in how you read the outcome.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.
How to read this chart
60‑month range $0.5378 – $0.9820 · fair‑value band $1.00 – $1.88 · the $0.9760 price screens below the $1.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 20, 2026.
Analysis
BioPharma Credit PLC (BPCR) currently trades at $0.9760, while our model-based Fair Value estimate is $1.50, implying the stock looks roughly 53.7% undervalued today. The Quality Score stands at 75/100 (high quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, BioPharma Credit PLC generated revenue of $158M at a net margin of 82.3%. Revenue grew 4.3% year over year. It earns a return on equity of 11.1%. The balance sheet holds a net cash position of $12.6M. Fundamentals as of Aug 20, 2026
Our scenario range runs from $1.00 (bear case) to $1.88 (bull case); at $0.9760, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 2% below its 52-week high and 25% above its 52-week low, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -33% fair-value upside, at 54%, BPCR screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 12 models by family
Widest divergence: DCF Models ($1.50) versus Earnings-Based ($0.7500). Highest evidence: Residual Income (76).
Notify me when BPCR reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 71 · Market factors (momentum, volatility) 73
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in London, the United Kingdom.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BioPharma Credit PLC reported revenue of $140M in FY2025 versus $88.0M in FY2021, a compound +12.4%/yr. Reported net income was $130M in FY2025, compounding +11.2%/yr from FY2021.
Watch BPCR: get an alert when its fair value changes →
Peer Group
Asset Management · 706 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Asset Management median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Asset Management stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| BlackRock, Inc BLK | $1,161 | $465.75 | -60% |
| Blackstone Inc BX | $146.41 | $52.88 | -64% |
| Investor AB INVEB | kr 417.90 | kr 835.80 | +100% |
| AB Industrivärden INDUA | kr 544.00 | kr 375.93 | -31% |
| ICICIAMC ICICIAMC | ₹3,077 | ₹1,132 | -63% |
| Hedef Holding HEDEF | 267.25 TRY | 321.44 TRY | +20% |
| Jio Financial Services Limited JIOFIN | ₹256.05 | ₹171.84 | -33% |
| Bajaj Holdings BAJAJHLDNG | ₹11,294 | ₹11,257 | -0% |
| HDFC Asset Management Company HDFCAMC | ₹2,490 | ₹866.78 | -65% |
| Nippon Life Asset Management Limited NAMINDIA | ₹1,182 | ₹311.00 | -74% |
Compare BioPharma Credit PLC with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is BioPharma Credit PLC (BPCR) overvalued or undervalued?
What is the fair value of BPCR?
What is the quality score of BPCR?
What is the revenue of BioPharma Credit PLC (BPCR)?
What is the net profit margin of BPCR?
Does BioPharma Credit PLC pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track BioPharma Credit PLC and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.